Found 463 results in Expert Content

Summary: This webinar aims to provide clarity on the types of molecules suitable for an ODT format as well as the regulatory pathways for new and established therapies.

Summary: This webinar provides an overview of co-amorphous research and its recent findings, particularly, the impact of low molecular weight excipient on developability, stability and solubility.

Summary: Learn about the current challenges in pediatric drug development programs including predicting oral absorption, and in vitro and in silico methods that can be applied to predict behavior in pediatric populations.

Summary: In this webinar, Catalent experts will explain how the phase appropriate expertise and technologies of the OneXpress® Solution can help streamline development and manufacturing, speed up your program timelines and reduce risks to transform your science into a successful treatment.

Summary: In this webinar, we explain why a lipid drug development platform can meet the need for speed to clinic and how the innovative lipid excipients and technologies could solve formulation challenges, optimizing bioavailability for early phase molecules, improve patient compliance and bring products faster to market.

Summary: Three early drug development experts present insights and techniques to help your clients get their molecules from preclinical to Phase 1 studies.

Summary: Phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization.

Summary: Experts introduce Catalent’s new OptiDose™ Design Solution, an integrated dose form design strategy based on an analyzation of your molecule, patient, and market.

Summary: Drug development requires integrating multi-disciplinary business, regulatory and scientific activities. To successfully support a client’s program, it is imperative to provide advice and services that support all three in the context of a program’s goal. In this exclusive webinar presented by Jim Spavins...

Summary: Catalent expands its inhalation platform through the acquisition of a Boston-area facility, providing spray drying, powder encapsulation and blister packaging for Dry Powder Inhaler (DPI) capsules.